Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $15.3333.
A number of equities analysts have commented on COYA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Coya Therapeutics in a report on Friday, July 17th. Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Roth Capital assumed coverage on Coya Therapeutics in a research report on Friday, June 5th. They set a "buy" rating and a $12.00 target price on the stock. Finally, Chardan Capital reiterated a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, August 12th.
View Our Latest Stock Analysis on Coya Therapeutics
Coya Therapeutics Stock Down 2.2%
Shares of NASDAQ:COYA opened at $4.86 on Friday. The company has a market capitalization of $114.02 million, a price-to-earnings ratio of -4.54 and a beta of 0.60. The company has a 50 day moving average of $4.89 and a two-hundred day moving average of $4.67. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.75.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.07. The business had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.13 million. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. On average, equities analysts anticipate that Coya Therapeutics will post -1.44 earnings per share for the current year.
Hedge Funds Weigh In On Coya Therapeutics
Institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. bought a new stake in shares of Coya Therapeutics in the fourth quarter worth $4,640,000. AWM Investment Company Inc. bought a new position in Coya Therapeutics during the 4th quarter valued at $4,205,000. Private Management Group Inc. bought a new position in Coya Therapeutics during the 4th quarter valued at $1,626,000. Marshall Wace LLP grew its holdings in Coya Therapeutics by 438.8% during the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company's stock worth $1,307,000 after acquiring an additional 183,533 shares in the last quarter. Finally, Dauntless Investment Group LLC grew its holdings in Coya Therapeutics by 199.5% during the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company's stock worth $872,000 after acquiring an additional 101,932 shares in the last quarter. 39.75% of the stock is owned by institutional investors and hedge funds.
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.
Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
